Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Fresh from the Pipeline
  • Published:

Telavancin

Nature Reviews Drug Discovery volume 8, pages 929–930 (2009)Cite this article

Abstract

In September 2009, telavancin (Vibativ; Theravance/Astellas Pharma), a lipoglycopeptide antibiotic, was approved by the US FDA for the treatment of adult patients with complicated skin and skin structure infections.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Telavancin.

References

  1. Van Bambeke, F. Glycopeptides in clinical development: pharmacological profile and clinical perspectives. Curr. Opin. Pharmacol. 4, 471–478 (2004).

    Article  CAS  Google Scholar 

  2. Leadbetter, M. R. et al. Hydrophobic vancomycin derivatives with improved ADME properties: discovery of telavancin (TD-6424). J. Antibiot. 57, 326–336 (2004).

    Article  CAS  Google Scholar 

  3. Hegde, S. S. et al. Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against Gram-positive bacteria. Antimicrob. Agents Chemother. 48, 3043–3050 (2004).

    Article  CAS  Google Scholar 

  4. Food and Drug Administration. FDA labelling information. FDA website [online] (2009).

  5. Higgins, D. L. et al. Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 49, 1127–1134 (2005).

    Article  CAS  Google Scholar 

  6. Lunde, C. S. et al. Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II. Antimicrob. Agents Chemother. 53, 3375–3383 (2009).

    Article  CAS  Google Scholar 

  7. Krause, K. M. et al. In vitro activity of telavancin against resistant Gram-positive bacteria. Antimicrob. Agents Chemother. 52, 2647–2652 (2008).

    Article  CAS  Google Scholar 

  8. Stryjewski, M. E. et al. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by Gram-positive organisms. Clin. Infect. Dis. 46, 1683–1693 (2008).

    Article  CAS  Google Scholar 

  9. King, M. D. et al. Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections. Ann. Intern. Med. 144, 309–317 (2006).

    Article  Google Scholar 

  10. Moran, G. J. et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N. Engl. J. Med. 355, 666–674 (2006).

    Article  CAS  Google Scholar 

  11. Wang, G. et al. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J. Clin. Microbiol. 44, 3883–3886 (2006).

    Article  CAS  Google Scholar 

  12. Tenover, F. C. Vancomycin-resistant Staphylococcus aureus: a perfect but geographically limited storm? Clin. Infect. Dis. 46, 675–677 (2008).

    Article  CAS  Google Scholar 

  13. Sun, H. K. et al. Tissue penetration of telavancin after intravenous administration in healthy subjects. Antimicrob. Agents Chemother. 50, 788–790 (2006).

    Article  CAS  Google Scholar 

  14. IMS MIDAS (IMS Health, 2009).

  15. Sanderson, I. et al. Specialty Pharmaceuticals (Cowen and Company, 14 Sep 2009).

    Google Scholar 

  16. Urist, M. & Harr, S. JP Morgan North America Equity Research Report (JP Morgan & Chase, 23 Jul 2009).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. G. Ralph Corey and Martin E. Stryjewski are at Duke University Medical Center, Durham, North Carolina 27710, USA. corey001@mc.duke.edu,

    G. Ralph Corey & Martin E. Stryjewski

  2. Wim Weyenberg and Uma Yasothan are at IMS Health, 7 Harewood Avenue, London, NW1 6JB, UK. UYasothan@de.imshealth.com,

    Wim Weyenberg & Uma Yasothan

  3. Peter Kirkpatrick is at Nature Reviews Drug Discovery. p.kirkpatrick@nature.com,

    Peter Kirkpatrick

Authors
  1. G. Ralph Corey
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Martin E. Stryjewski
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wim Weyenberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Uma Yasothan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Peter Kirkpatrick
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

G.R.C. is the Principal Investigator for trials with telavancin. M.E.S. has received research grants from Theravance Inc. and currently he is a consultant to Theravance. M.E.S. has provided consulting services to Astellas in the past.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Corey, G., Stryjewski, M., Weyenberg, W. et al. Telavancin. Nat Rev Drug Discov 8, 929–930 (2009). https://doi.org/10.1038/nrd3051

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd3051

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing